Published November 17, 2017 by HCA News
“Marjorie A. Speers, Executive Director of the WCG Foundation, also had problems with Right to Try laws. Under the existing system, the process encourages deliberate decisions: first, the patient and their physician decide they want to pursue a drug undergoing clinical trial; then, they request that access from the drug’s maker and the company can decide if they believe the drug will be useful; finally, the FDA reviews and approves the request.
Right to Try, Speers argued, bypasses all of that, which could be detrimental. “These uses can only occur for desperately ill people, there’s no other treatment option for them,” she said. “It’s not necessarily the best time to be making a decision.”’
You can read the full article from Healthcare Analytics News HERE